Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
2
clinical trials
|
View Analysis
Sort by:
Newest First
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
Not Applicable
Not yet recruiting
Conditions
Acute Coronary Syndrome
Non ST Segment Elevation Acute Coronary Syndrome
Interventions
Drug: Cholesterol Absorption Inhibitor
Drug: Tafolecimab
Drug: Statin
Subscribe
First Posted Date
2023-10-24
Last Posted Date
2023-10-24
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
3684
Registration Number
NCT06096909
Subscribe
Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound
Phase 4
Completed
Conditions
Coronary Artery Disease
Hypercholesterolemia
Interventions
Drug: Lipitor (Atorvastatin) monotherapy
Drug: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]
Subscribe
First Posted Date
2010-01-06
Last Posted Date
2015-04-01
Lead Sponsor
Kumamoto University
Target Recruit Count
245
Registration Number
NCT01043380
Locations
🇯🇵
Kumamoto University, Kumamoto, Japan
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy